News | October 26, 2022
Novartis maintains growth momentum; Confirms FY’22 Group guidance
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Extended Phenytoin Sodium Capsules are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures
The company increases its efficiency and is able to face the growing demand for its services.
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Transformation to pure-play Innovative Medicines company nears completion
Celgene agreed to provide Dr. Reddy's with a license to sell volume-limited amounts of generic lenalidomide capsules in the U.S.
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
Sandoz is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US
Carbamazepine Tablets are indicated for use as an anticonvulsant drug and in the treatment of the pain associated with true trigeminal neuralgia
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
Subscribe To Our Newsletter & Stay Updated
